go back

Brexucabtagene Autoleucel (Tecartus) CAR-T Therapy

Delaware rates for HCPCS Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated October 2026.

How much rates vary

Facilitymedian $512,861 · 10th to 90th $512,861 to $512,861Professionalmedian $512,861 · 10th to 90th $512,861 to $512,861
$500Kfacility $512,861professional $512,861

Distribution of negotiated rates across all payers (price axis is log-scale). Small sample; interpret with caution. Need provider-level prices or 24+ months of history? Contact us.

Rates by insurance carrier

Insurance Carrier
Aetna
Setting
Facility
Modifier
None
Typical Low
$512,861.38
Median
$512,861.38
Typical High
$512,861.38
Aetna
Setting
Professional
Modifier
None
Typical Low
$512,861.38
Median
$512,861.38
Typical High
$512,861.38
Aetna
Setting
Professional
Modifier
52 · Reduced service
Typical Low
$257,039.58
Median
$257,039.58
Typical High
$257,039.58
Aetna
Setting
Professional
Modifier
53 · Discontinued
Typical Low
$102,329.30
Median
$102,329.30
Typical High
$102,329.30
Aetna
Setting
Professional
Modifier
55 · Aftercare only
Typical Low
$75,857.76
Median
$75,857.76
Typical High
$75,857.76
Aetna
Setting
Professional
Modifier
56 · Pre-op care only
Typical Low
$51,286.14
Median
$51,286.14
Typical High
$51,286.14
United
Setting
Professional
Modifier
None
Typical Low
$446,683.59
Median
$741,310.24
Typical High
$741,310.24